1. Home
  2. ON vs ALNY Comparison

ON vs ALNY Comparison

Compare ON & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ON Semiconductor Corporation

ON

ON Semiconductor Corporation

HOLD

Current Price

$118.28

Market Cap

43.9B

Sector

Technology

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$292.75

Market Cap

38.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ON
ALNY
Founded
1992
2002
Country
United States
United States
Employees
N/A
115
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.9B
38.4B
IPO Year
2000
2004

Fundamental Metrics

Financial Performance
Metric
ON
ALNY
Price
$118.28
$292.75
Analyst Decision
Buy
Strong Buy
Analyst Count
25
28
Target Price
$65.29
$471.00
AVG Volume (30 Days)
11.1M
1.1M
Earning Date
05-04-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
206.88
EPS
N/A
2.33
Revenue
$5,878,300,000.00
$1,037,418,000.00
Revenue This Year
$7.93
$52.67
Revenue Next Year
$8.90
$31.48
P/E Ratio
N/A
$126.31
Revenue Growth
N/A
22.88
52 Week Low
$44.56
$273.11
52 Week High
$134.92
$495.55

Technical Indicators

Market Signals
Indicator
ON
ALNY
Relative Strength Index (RSI) 50.95 50.26
Support Level $51.30 $284.69
Resistance Level $119.10 $314.04
Average True Range (ATR) 7.56 9.72
MACD -1.40 0.78
Stochastic Oscillator 39.49 58.39

Price Performance

Historical Comparison
ON
ALNY

About ON ON Semiconductor Corporation

Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: